Suppr超能文献

125碘标记的凝血因子VIII在正常人和典型血友病患者体内的存活情况。关于人凝血因子VIII异质性的观察。

Survival of 125iodine-labeled Factor VIII in normals and patients with classic hemophilia. Observations on the heterogeneity of human Factor VIII.

作者信息

Over J, Sixma J J, Bruïne M H, Trieschnigg M C, Vlooswijk R A, Beeser-Visser N H, Bouma B N

出版信息

J Clin Invest. 1978 Aug;62(2):223-34. doi: 10.1172/JCI109120.

Abstract

Radiolabeled human Factor VIII was used to study its survival in normals and patients with classic hemophilia, and to study the heterogeneity of Factor VIII; Purified Factor VIII was radiolabeled with 125iodine (125I-VIII) without loss of its structural integrity. The survival of 125I-VIII was studied in six normals and six hemophiliacs of whom four of the hemophiliacs had received transfusions with normal cryoprecipitate before the 125I-VIII infusion. No significant difference was observed between the disappearance of Factor VIII coagulant activity and radioactivity in these hemophiliacs. 125I-VIII in plasma showed a biphasic disappearance with an average t1/2 of 2.9 +/- 0.4 h (SEM) for the first phase and 18.6 +/- 0.7 h (SEM) for the second phase, respectively. The survival of 125I-VIII was similar comparing normals and hemophiliacs. The highest molecular weight forms of Factor VIII disappear more rapidly than the lower molecular weight ones. This was established by analysis of the fractions obtained by gel chromatography of plasma collected at several times after infusion and by analysis of the in vivo disappearance of three subfractions of Factor VIII. The fraction of 125I-VIII binding to platelets in the presence of ristocetin (containing the highest molecular weight forms of Factor VIII including the ristocetin cofactor) represented about 50% of the radioactivity present in plasma after infusion and showed a t 1/2 of 11.7 +/- 0.9 h (SEM) for the second phase. The fraction, which was recovered in cryoprecipitate of the recipient's plasma, represented about 90% of the initial radioactivity and showed a t 1/2 of 16.3 +/- 0.8 h (SEM) for the second phase. The fraction of 125I-VIII remaining in the cryosupernatant plasma (containing low molecular weight forms of Factor (VIII) showed a t 1/2 of 27.2 +/- 1.1 h (SEM). The first phase of the disappearance of 125I-VIII is caused in part by the disappearance of the highest molecular weight forms, which are possibly removed by the reticuloendothelial system.

摘要

放射性标记的人凝血因子VIII被用于研究其在正常人及典型血友病患者体内的存活情况,以及研究凝血因子VIII的异质性;纯化的凝血因子VIII用125碘(125I-VIII)进行放射性标记,且其结构完整性未受损失。在6名正常人及6名血友病患者中研究了125I-VIII的存活情况,其中4名血友病患者在输注125I-VIII之前接受过正常冷沉淀的输血。在这些血友病患者中,未观察到凝血因子VIII凝血活性和放射性消失之间存在显著差异。血浆中的125I-VIII呈现双相消失,第一相的平均半衰期为2.9±0.4小时(标准误),第二相为18.6±0.7小时(标准误)。比较正常人和血友病患者时,125I-VIII的存活情况相似。凝血因子VIII分子量最高的形式比分子量较低的形式消失得更快。这是通过对输注后不同时间采集的血浆进行凝胶色谱分析所得组分以及对凝血因子VIII的三个亚组分在体内的消失情况分析得以证实的。在瑞斯托霉素存在的情况下,与血小板结合的125I-VIII组分(包含分子量最高的凝血因子VIII形式,包括瑞斯托霉素辅因子)占输注后血浆中放射性的约50%,第二相的半衰期为11.7±0.9小时(标准误)。在受者血浆冷沉淀中回收的组分占初始放射性的约90%,第二相的半衰期为16.3±0.8小时(标准误)。留在冷上清血浆中的125I-VIII组分(包含低分子量的凝血因子VIII形式)的半衰期为27.2±1.1小时(标准误)。125I-VIII消失的第一相部分是由分子量最高的形式的消失所致,这些形式可能被网状内皮系统清除。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/63fb/371757/d8263daed62a/jcinvest00668-0003-a.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验